Interesting, the two patients (one in each dose level group) with disease progression in our ongoing P1 CHM1101 trial also happen to be the ones that received the least number of doses, while the other five patients with more than 3 doses received achieved disease control for glioblastoma:
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $50.77K | 12.69M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2602327 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 18629873 | 23 |
View Market Depth
| Last trade - 15.15pm 25/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |